Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microchimerism, GVHD, and tolerance in solid organ transplantation.

D J Triulzi1, M A Nalesnik

  • 1Department of Pathology, University of Pittsburgh Medical Center and the Institute for Transfusion Medicine, Pittsburgh, PA 15213, USA. dtriulzi@itxm.org

Transfusion
|March 29, 2001
PubMed
Summary

Microchimerism aids graft tolerance, but donor hematopoietic progenitor cell (HPC) infusions can cause graft-versus-host disease (GVHD). While rare, GVHD cases suggest caution with specific donor types, but not routine blood component irradiation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Dead Sea needs salt water… massively bleeding patients need whole blood: The evolution of blood product resuscitation.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2019
Same author

The red blood cell unit and ice configuration in portable coolers is important in maintaining acceptable storage air temperature.

Transfusion medicine (Oxford, England)·2018
Same author

Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques.

Vox sanguinis·2017
Same author

The effects of a data driven maximum surgical blood ordering schedule on preoperative blood ordering practices.

Hematology (Amsterdam, Netherlands)·2017
Same author

Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm.

Vox sanguinis·2016
Same author

Measurement of haemolysis markers following transfusion of uncrossmatched, low-titre, group O+ whole blood in civilian trauma patients: initial experience at a level 1 trauma centre.

Transfusion medicine (Oxford, England)·2016

Area of Science:

  • Immunology
  • Transplantation Biology
  • Cellular Therapy

Background:

  • Microchimerism is studied for its role in long-term graft tolerance.
  • Donor hematopoietic progenitor cell (HPC) infusions are emerging therapies to enhance tolerance.
  • Graft-versus-host disease (GVHD) is an adverse outcome of host-donor white blood cell (WBC) interactions.

Purpose of the Study:

  • To investigate the relationship between microchimerism and graft tolerance.
  • To evaluate the incidence and implications of GVHD in solid organ transplantation.
  • To assess the impact of donor HPC infusions on GVHD and graft rejection.

Main Methods:

  • Review of reported cases of GVHD in solid organ transplant recipients.
  • Analysis of outcomes associated with donor HPC infusions, including GVHD and rejection episodes.

Related Experiment Videos

  • Evaluation of specific donor characteristics, such as HLA homozygosity, in relation to GVHD risk.

    • Main Results:

    • GVHD is a rare complication, most frequently reported in liver transplantation.
    • Two cases of GVHD in recipients from donors homozygous for a shared HLA haplotype suggest avoiding such donors.
    • TA-GVHD is extremely rare in solid organ recipients; existing cases do not support routine blood component irradiation.
    • Donor HPC infusions increase GVHD incidence (usually mild) but decrease rejection severity and frequency.

    Conclusions:

    • The use of specific donor types homozygous for shared HLA haplotypes warrants careful consideration due to GVHD risk.
    • Routine irradiation of cellular blood components for all solid organ transplant recipients is not supported by current evidence.
    • Donor HPC infusions show promise in enhancing graft tolerance and reducing rejection, though long-term graft survival effects are under investigation.